Tourmaline Bio/$TRML

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX

About Tourmaline Bio

Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.

Ticker

$TRML
Sector
Health Care
Primary listing
NASDAQ

Industry

Biotechnology
Headquarters
New York, United States

Employees

74

ISIN

US89157D1054
Website
www.tourmalinebio.com

Tourmaline Bio Metrics

BasicAdvanced
$422M
-
-$3.22
-
-

What the Analysts think about Tourmaline Bio

Analyst ratings (Buy, Hold, Sell) for Tourmaline Bio stock.

Bulls say / Bears say

LifeSci Capital initiated coverage of Tourmaline Bio with an 'Outperform' recommendation, suggesting a potential upside of 376.60% from its latest reported closing price. (nasdaq.com)
Tourmaline Bio's Phase 2 TRANQUILITY trial was over-enrolled with 143 participants, exceeding the original target of 120, indicating strong interest and potential for positive outcomes. (stocktitan.net)
The company reported a robust cash position of $294.9 million as of December 31, 2024, providing financial runway into the second half of 2027, supporting ongoing and future clinical trials. (stocktitan.net)
Tourmaline Bio reported a net loss of $73.2 million for the full year 2024, with a basic and diluted net loss per share of $2.89, reflecting significant operational expenses. (stocktitan.net)
Research and development expenses increased to $66.99 million in 2024 from $32.37 million in 2023, indicating rising costs that may impact profitability. (stockanalysis.com)
The company's short interest stands at 11.92% of outstanding shares, suggesting that a notable portion of investors are betting against the stock. (stockanalysis.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.

Tourmaline Bio Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Tourmaline Bio Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Tourmaline Bio News

AllArticlesVideos
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

GlobeNewsWire·1 month ago
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TRML

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs